Phase II of Singapore s National Precision Medicine strategy to begin in April 2021
Precision medicine is part of Singapore s Research, Innovation and Enterprise (RIE) 2025 strategic goal to transform and protect the health of every Singaporean. Identified as a priority by the Ministry of Health, precision medicine aims to understand how genomic, phenotypic, lifestyle and clinical factors contribute to the health of Singaporeans. It also supports the responsible use of health data in clinical applications with the longer-term goal of addressing Singapore s healthcare challenges in a sustainable and clinically cost-effective manner.
Singapore s National Precision Medicine (NPM) strategy is a 10-year plan to enhance and accelerate Singapore s biomedical research, health outcomes and economic growth. NPM is a whole-of-government effort to establish the necessary frameworks and infrastructure to realise precision medicine on a national scale, to ultimately improve public health, enhanc
• Sets pace for targeted therapy development among those diagnosed
22 December 2020, Singapore – For over 20 years, the Genetics Service at the KK Women’s and Children’s Hospital (KKH) has been providing clinical care to patients with genetic disorders. In 2014, BRIDGES (Bringing Research Innovations for the Diagnosis of GEnetic diseases in Singapore) was set up, in collaboration with genomic research institutes at SingHealth, Agency for Science, Technology and Research (A STAR) and Duke-NUS to synergise the diagnostic efforts and patient outcome management.
After six years, the KKH has met the goals set out in its BRIDGES programme, achieving 39 per cent in diagnostic yield through identifying more patients with genetic mutations. This result is on par with similar research programmes globally which have a diagnostic yield of 25 to 40 per cent.
Credit: A STAR s Genome Institute of Singapore (GIS)
22 December 2020, Singapore - For over 20 years, the Genetics Service at the KK Women s and Children s Hospital (KKH) has been providing clinical care to patients with genetic
disorders. In 2014, BRIDGES (Bringing Research Innovations for the Diagnosis of GEnetic diseases in Singapore) was set up, in collaboration with genomic research institutes at SingHealth, Agency for Science, Technology and Research (A STAR) and Duke-NUS to synergise the diagnostic efforts and patient outcome management.
After six years, the KKH has met the goals set out in its BRIDGES programme, achieving 39 per cent in diagnostic yield through identifying more patients with genetic mutations. This result is on par with similar research programmes globally which have a diagnostic yield of 25 to 40 per cent.
Researchers establish BRIDGES program to synergize diagnostic efforts, patient outcome management
For over 20 years, the Genetics Service at the KK Women s and Children s Hospital (KKH) has been providing clinical care to patients with genetic disorders. In 2014, BRIDGES (Bringing Research Innovations for the Diagnosis of GEnetic diseases in Singapore) was set up, in collaboration with genomic research institutes at SingHealth, Agency for Science, Technology and Research (A STAR) and Duke-NUS to synergize the diagnostic efforts and patient outcome management.
After six years, the KKH has met the goals set out in its BRIDGES program, achieving 39 per cent in diagnostic yield through identifying more patients with genetic mutations. This result is on par with similar research programmes globally which have a diagnostic yield of 25 to 40 per cent.